🔷 Approval is supported by positive Phase III ARANOTE data, enabling physicians to better tailor treatment plans for men with mHSPC.

🔗 Read more: bit.ly/ONCOnews04Fe...

#ONCOnews #OncoAlert #OncEd #Nubeqa #Darolutamide #ProstateCancer #mHSPC #ClinicalTrials

Learn how PTEN deficiency impacts prognosis and treatment selection, with practical insights on testing and emerging PI3K/AKT-targeted approaches.

👉 Access the program now. bit.ly/49dqZln

#HCPEducation #mHSPC #ProstateCancer #Oncology #Urology 

Bayer's prostate cancer drug Nubeqa cleared for NHS use Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

#menshealth #NICErecommended #Bayer #prostatecancer #Nubeqa #darolutamide #Nubeqaregimen #hormonesensitiveprostatecancer #HSPC #androgendeprivationtherapy #ProstateCancerUK #advancedHSPC #ARANOTEtrial #castrationresistantprostatecancer #CRPC #mHSPC #NationalProstateCancerAudit #NPCA
zurl.co/dDIIm

“PARPi may be approved in the mHSPC setting in the near future.” – @neerajagarwal.bsky.social at #ESMO25.

Ongoing trials could expand the reach of precision therapy beyond mCRPC

#ProstateCancer #Oncology #OncTwitter #MedEd #MedX #mPC #mHSPC

STAMPEDE Trial: Metformin in Metastatic Prostate Cancer STAMPEDE trial findings on the addition of metformin to standard treatment in mHSPC. Learn about survival and metabolic outcomes.

New Paper Alert: STAMPEDE Trial Results on Metformin in Metastatic Prostate Cancer Treatment

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #STAMPEDE #ProstateCancer #mPC #Metformin #mHSPC

Positive findings from the CAPTURE and AMPLITUDE trials highlight the importance of early testing patients for BRCA and HRR mutations.

Read the opinion by @ecastromarcos.bsky.social‬ in the #ESMODailyReporter

🔗 buff.ly/b4cgGKB

#ProstateCancer #mHSPC #PersonalisedMedicine

KEYNOTE-991. Pembrolizumab Fails to Improve OS in mHSPC KEYNOTE-991 trial shows no survival benefit from adding pembrolizumab to enzalutamide and ADT in mHSPC.

KEYNOTE-991 Trial Results: Pembrolizumab Plus Enzalutamide and ADT in mHSPC

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #KEYNOTE-991 #IO #ADT #Pembrolizumab #Enzalutamide #mHSPC #ProstateCancer

🎥 New on #OncologyBytes from #IUCS2024

Dr. Mona Hassan on low-volume mHSPC:
📊 PSA may be a key prognostic factor.
📉 Treatment patterns remain inconsistent.

📺 Watch: youtu.be/UNbeQ2Gv8iE

🌐 Learn more at: oncoassist.com

#mHSPC #ProstateCancer #RealWorldData #Oncoassist #oncoalert

🎥 New on #OncologyBytes from #IUCS2024
Dr. Fabrizio Di Costanzo: Can TK1 track treatment response in mHSPC?
📉 Early data shows TK1 & PSA decline together in most patients.
📺 Watch: youtu.be/3w44UNUP890
🌐 Learn more at: oncoassist.com
#ProstateCancer #Biomarkers #mHSPC #TK1 #Oncoassist #CancerCare

Another good summary of @anzuptrials.bsky.social / Prof Louise Emmett’s #ENZA-p trial outcomes that were shared at the recent @ascocancer.bsky.social #ASCOGU25 conference and published in @thelancet.bsky.social
#prostatecancer #mHSPC #clinicaltrials

ASCO Publications

Terapia con darolutamida y terapia de deprivación androgénica es eficaz y tolerable en pacientes con cáncer de próstata metastásico sensible a hormona, mejorando la supervivencia libre de progresión radiológica y la seguridad #darolutamide #ADT #mHSPC ascopubs.org/doi/full/10....

NCODA's PQI simplifies the use of Darolutamide with Docetaxel for mHSPC - OncoDaily NCODA's PQI simplifies the use of Darolutamide with Docetaxel for mHSPC / cancer, darolutamide, docetaxel, Metastatic Hormone-sensitive Prostate Cancer,

NCODA’s PQI simplifies the use of Darolutamide with Docetaxel for mHSPC

oncodaily.com/insight/201195

#Cancer #Darolutamide #Docetaxel #ProstateCancer #MetastaticProstateCancer #mHSPC #NCODA #NCODAPQI #OncoDaily #Oncology #PQIinAction

Just in @bjuijournal.bsky.social: Our #TITAN post hoc analysis: Patients with ultralow 0.2 #PSA derived greatest benefit. Less pronounced addtl. benefit for .02
#mHSPC #ProstateCancer
👉bjui-journals.onlinelibrary.wiley.com/doi/full/10.1111/bju.164... @oncoalert.bsky.social @uroweb.bsky.social